MonumenTAL-1: Safety Outcomes
Panelists discuss how the extended follow-up data from MonumenTAL-1 show consistent safety outcomes for talquetamab with manageable discontinuation rates due to skin changes and weight loss, while acknowledging that GPRC5D targeting creates unique toxicities including nail and skin changes that require proactive management strategies, particularly as treatment transitions from academic centers to community practice where quality-of-life considerations become increasingly important.
EP: 1.MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data
EP: 2.MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data (Part 2)
EP: 3.Data Review of Teclistamab and Elranatamab in R/R MM
EP: 4.Expert Opinion on Modern Availability of Several Agents
EP: 5.Future of R/R MM: Emerging Bispecifics and Trispecifics
EP: 6.Optimal Dosing of Talquetamab
EP: 7.Optimal Dosing of Talquetamab (Part 2)
EP: 8.Talquetamab: Real-World Outcomes With Outpatient Dosing
EP: 9.Teclistamab: OPTEC Trial Overview
EP: 10.MonumenTAL-1: Safety Outcomes
MonumenTAL-1 Safety Outcomes
Extended follow-up data from the MonumenTAL-1 trial continue to demonstrate consistent safety profiles with no new discontinuations attributed to weight loss and skin changes, which are characteristic toxicities associated with GPRC5D targeting. The infection rate remains stable at approximately 20% to 26%, consistent with previous reports, highlighting the importance of ongoing infectious disease monitoring and prophylaxis strategies. These safety findings support the long-term tolerability of talquetamab, particularly important given the chronic nature of multiple myeloma treatment and the need for sustained therapy administration.
The unique toxicity profile associated with GPRC5D targeting, including skin and nail changes, presents management challenges that require specialized approaches. Since GPRC5D represents a relatively new therapeutic target, understanding the underlying physiology and developing optimal management strategies for these specific adverse events remains an area of active investigation. The ability to effectively manage these toxicities will be crucial for successful implementation in community practice settings, where specialized dermatologic support may be more limited compared with academic medical centers.
Ongoing studies are examining strategies to optimize the management of GPRC5D-related toxicities and their impact on patient quality of life. These investigations will be essential for developing standardized approaches to toxicity management that can be implemented across different practice settings. The results of these studies, expected in the coming months, should provide valuable guidance on best practices for managing the unique adverse effect profile of GPRC5D-targeted therapies, ultimately supporting broader adoption and improved patient outcomes while maintaining treatment adherence and quality of life during therapy.
